Sylvanie Surget

Cell Death via DR5, but not DR4, Is Regulated by p53 in Myeloma Cells

Sylvanie Surget, David Chiron, Patricia Gomez‐Bougie et al. · Cancer Research · 2012 · 63 citations

Medicine, Oncology, Pharmacology +17

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma

Georgina S.F. Anderson, José Ballester‐Beltrán, George Giotopoulos et al. · Blood · 2022 · 39 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +16

Autocrine insulin-like growth factor 1 and stem cell factor but not interleukin 6 support self-renewal of human myeloma cells

David Chiron, Sophie Maïga, Sylvanie Surget et al. · Blood Cancer Journal · 2013 · 25 citations · Full text

Medicine, Cell Biology, Oncology +13

RITA (Reactivating p53 and Inducing Tumor Apoptosis) is efficient against TP53 abnormal myeloma cells independently of the p53 pathway

Sylvanie Surget, Géraldine Descamps, Carole Brosseau et al. · BMC Cancer · 2014 · 23 citations · Full text

Medicine, Oncology, Pharmacology +17

Bendamustine and melphalan kill myeloma cells similarly through reactive oxygen species production and activation of the p53 pathway and do not overcome resistance to each other

Sylvanie Surget, Émilie Lemieux‐Blanchard, Sophie Maïga et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2013 · 20 citations

Medicine, Oncology, Pharmacology +17